270 related articles for article (PubMed ID: 20807817)
1. BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma.
Ibrahim N; He L; Leong CO; Xing D; Karlan BY; Swisher EM; Rueda BR; Orsulic S; Ellisen LW
Cancer Res; 2010 Sep; 70(18):7155-65. PubMed ID: 20807817
[TBL] [Abstract][Full Text] [Related]
2. The presence of an intronic deletion in p73 and high levels of ZEB1 alter the TAp73/DeltaTAp73 ratio in colorectal carcinomas.
Domínguez G; Peña C; Silva J; García JM; García V; Rodríguez R; Cantos B; Citores MJ; España P; Bonilla F
J Pathol; 2006 Dec; 210(4):390-7. PubMed ID: 17029218
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.
Concin N; Hofstetter G; Berger A; Gehmacher A; Reimer D; Watrowski R; Tong D; Schuster E; Hefler L; Heim K; Mueller-Holzner E; Marth C; Moll UM; Zeimet AG; Zeillinger R
Clin Cancer Res; 2005 Dec; 11(23):8372-83. PubMed ID: 16322298
[TBL] [Abstract][Full Text] [Related]
4. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers.
Leong CO; Vidnovic N; DeYoung MP; Sgroi D; Ellisen LW
J Clin Invest; 2007 May; 117(5):1370-80. PubMed ID: 17446929
[TBL] [Abstract][Full Text] [Related]
5. TAp73-mediated the activation of c-Jun N-terminal kinase enhances cellular chemosensitivity to cisplatin in ovarian cancer cells.
Zhang P; Liu SS; Ngan HY
PLoS One; 2012; 7(8):e42985. PubMed ID: 22900074
[TBL] [Abstract][Full Text] [Related]
6. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo.
Concin N; Becker K; Slade N; Erster S; Mueller-Holzner E; Ulmer H; Daxenbichler G; Zeimet A; Zeillinger R; Marth C; Moll UM
Cancer Res; 2004 Apr; 64(7):2449-60. PubMed ID: 15059898
[TBL] [Abstract][Full Text] [Related]
7. TAp73 and ΔNp73 have opposing roles in 5-aza-2'-deoxycytidine-induced apoptosis in breast cancer cells.
Lai J; Yang F; Zhang W; Wang Y; Xu J; Song W; Huang G; Gu J; Guan X
Mol Cells; 2014 Aug; 37(8):605-12. PubMed ID: 25134538
[TBL] [Abstract][Full Text] [Related]
8. TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC).
Bunch B; Krishnan N; Greenspan RD; Ramakrishnan S; Attwood K; Yan L; Qi Q; Wang D; Morrison C; Omilian A; Bshara W; Pili R; Trump DL; Johnson C; Woloszynska A
Cell Cycle; 2019 Sep; 18(17):2055-2066. PubMed ID: 31318640
[TBL] [Abstract][Full Text] [Related]
9. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas.
Swisher EM; Gonzalez RM; Taniguchi T; Garcia RL; Walsh T; Goff BA; Welcsh P
Mol Cancer; 2009 Jul; 8():48. PubMed ID: 19602291
[TBL] [Abstract][Full Text] [Related]
10. A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma.
Ory B; Ramsey MR; Wilson C; Vadysirisack DD; Forster N; Rocco JW; Rothenberg SM; Ellisen LW
J Clin Invest; 2011 Feb; 121(2):809-20. PubMed ID: 21293058
[TBL] [Abstract][Full Text] [Related]
11. p53 inactivation upregulates p73 expression through E2F-1 mediated transcription.
Tophkhane C; Yang SH; Jiang Y; Ma Z; Subramaniam D; Anant S; Yogosawa S; Sakai T; Liu WG; Edgerton S; Thor A; Yang X
PLoS One; 2012; 7(8):e43564. PubMed ID: 22952705
[TBL] [Abstract][Full Text] [Related]
12. CK2 phosphorylates and inhibits TAp73 tumor suppressor function to promote expression of cancer stem cell genes and phenotype in head and neck cancer.
Lu H; Yan C; Quan XX; Yang X; Zhang J; Bian Y; Chen Z; Van Waes C
Neoplasia; 2014 Oct; 16(10):789-800. PubMed ID: 25379016
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of E2F1 in human gastric carcinoma is involved in anti-cancer drug resistance.
Yan LH; Wei WY; Cao WL; Zhang XS; Xie YB; Xiao Q
BMC Cancer; 2014 Dec; 14():904. PubMed ID: 25466554
[TBL] [Abstract][Full Text] [Related]
14. deltaEF1 repressor controls selectively p53 family members during differentiation.
Fontemaggi G; Gurtner A; Damalas A; Costanzo A; Higashi Y; Sacchi A; Strano S; Piaggio G; Blandino G
Oncogene; 2005 Nov; 24(49):7273-80. PubMed ID: 16007124
[TBL] [Abstract][Full Text] [Related]
15. Runt-related transcription factor 2 attenuates the transcriptional activity as well as DNA damage-mediated induction of pro-apoptotic TAp73 to regulate chemosensitivity.
Ozaki T; Sugimoto H; Nakamura M; Hiraoka K; Yoda H; Sang M; Fujiwara K; Nagase H
FEBS J; 2015 Jan; 282(1):114-28. PubMed ID: 25331851
[TBL] [Abstract][Full Text] [Related]
16. Regulating p73 isoforms in human tumours.
Coates PJ
J Pathol; 2006 Dec; 210(4):385-9. PubMed ID: 17044134
[TBL] [Abstract][Full Text] [Related]
17. p73 competes with p53 and attenuates its response in a human ovarian cancer cell line.
Vikhanskaya F; D'Incalci M; Broggini M
Nucleic Acids Res; 2000 Jan; 28(2):513-9. PubMed ID: 10606650
[TBL] [Abstract][Full Text] [Related]
18. JNK-NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress.
Kostecka A; Sznarkowska A; Meller K; Acedo P; Shi Y; Mohammad Sakil HA; Kawiak A; Lion M; Królicka A; Wilhelm M; Inga A; Zawacka-Pankau J
Cell Death Dis; 2014 Oct; 5(10):e1484. PubMed ID: 25341038
[TBL] [Abstract][Full Text] [Related]
19. Differential regulation of p73 variants in response to cisplatin treatment in SH-SY5Y neuroblastoma cells.
Million K; Horvilleur E; Goldschneider D; Agina M; Raguénez G; Tournier F; Bénard J; Douc-Rasy S
Int J Oncol; 2006 Jul; 29(1):147-54. PubMed ID: 16773194
[TBL] [Abstract][Full Text] [Related]
20. GRAMD4 mimics p53 and mediates the apoptotic function of p73 at mitochondria.
John K; Alla V; Meier C; Pützer BM
Cell Death Differ; 2011 May; 18(5):874-86. PubMed ID: 21127500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]